You're asking about **2-(2-bromo-4-methylphenoxy)-N-(2-pyridinylmethyl)acetamide**. This is a rather specific chemical compound, and it's unlikely to have widespread recognition outside of specialized fields. Here's a breakdown:
**Understanding the Structure**
* **2-(2-bromo-4-methylphenoxy)-:** This part describes a substituted phenol.
* **Phenol:** A benzene ring with an -OH group attached.
* **2-bromo:** A bromine atom attached to the second carbon of the benzene ring.
* **4-methyl:** A methyl group (-CH3) attached to the fourth carbon of the benzene ring.
* **Phenoxy:** The phenol ring with the hydrogen on the -OH group replaced by another atom or group.
* **N-(2-pyridinylmethyl)-:** This part describes a substituted amide.
* **Amide:** A functional group containing a carbonyl group (C=O) connected to a nitrogen atom.
* **N-:** Indicates that the substituted group is directly attached to the nitrogen atom.
* **2-pyridinylmethyl:** A pyridinyl group (a nitrogen-containing aromatic ring) with a methylene group (-CH2-) connecting it to the amide nitrogen.
* **Acetamide:** The simplest amide, containing a methyl group (-CH3) connected to the carbonyl group.
**Putting it Together**
The entire molecule can be visualized as an acetamide with the following modifications:
* The hydrogen attached to the nitrogen is replaced by a 2-pyridinylmethyl group.
* The hydrogen on the carbonyl carbon is replaced by a 2-bromo-4-methylphenoxy group.
**Research Importance**
Without specific context, it's impossible to definitively state why this compound would be important. However, given its structure, it's likely that it has been synthesized or investigated for potential applications in:
* **Pharmaceutical Chemistry:** The combination of a substituted phenol, an amide, and a pyridinyl ring is common in drug molecules. This compound could be a lead compound for developing new drugs, possibly with activity against various targets.
* **Materials Science:** The presence of aromatic rings and a functional amide group suggests potential for use in materials with specific optical or electronic properties.
* **Organic Synthesis:** The compound might be a useful synthetic intermediate or reagent in the preparation of other more complex molecules.
**Finding Information**
To understand the exact research importance of this compound, you would need more information:
* **Where did you encounter this compound?** Was it mentioned in a research paper, patent, or other scientific resource?
* **What is the context?** What specific properties or applications are being studied?
With more information, it would be possible to find relevant research articles, patents, or databases that discuss the compound's significance.
ID Source | ID |
---|---|
PubMed CID | 740886 |
CHEMBL ID | 1569325 |
CHEBI ID | 114597 |
Synonym |
---|
BIM-0045174.P001 |
OPREA1_751346 |
STK091964 |
2-(2-bromo-4-methylphenoxy)-n-(pyridin-2-ylmethyl)acetamide |
CBMICRO_045419 |
EU-0043793 |
MLS000109940 |
smr000105873 |
CHEBI:114597 |
AKOS001639193 |
HMS2324J16 |
CHEMBL1569325 |
SR-01000482865-1 |
sr-01000482865 |
2-(2-bromo-4-methylphenoxy)-n-(2-pyridinylmethyl)acetamide |
Q27196001 |
Class | Description |
---|---|
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 16.9441 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
BRCA1 | Homo sapiens (human) | Potency | 17.7828 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 14.7883 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 4.4668 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.1623 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 50.1187 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 3.5481 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 2 (28.57) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.22) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |